Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study
Pharmacology · 2023
DOI: 10.1159/000532001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology, 2023. Verfasst von Chuwen Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Afibrinogenemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The aims of the study were to investigate the risk factors of tigecycline-induced hypofibrinogenemia and to evaluate the safety of tigecycline with concomitant antithrombotic drugs.
Methods
We performed a retrospective analysis of patients who received tigecycline for more than 3 days between January 2015 and June 2019. Clinical and laboratory data were collected including fibrinogen concertation, tigecycline dose, duration of treatment, disease severity, complete blood count, indicators of infection, liver and renal function. Risk factors of hypofibrinogenemia were analyzed by univariate and multivariate analysis. To evaluate the safety of tigecycline and concomitant antithrombotic drugs, bleeding events were assessed by comparing the decline in hemoglobin and the amount of red blood cell transfusion in patients with antithrombotic drugs and those without.
Results
This study included a total of 68 cases, 20 of which experienced hypofibrinogenemia while receiving tigecycline treatment. Duration of treatment, cefoperazone/sulbactam combination therapy, and fibrinogen levels prior to initiation of tigecycline were risk factors associated with tigecycline-induced hypofibrinogenemia. There were 26 recorded bleeding incidents, 25 of which happened before the start of tigecycline. Antithrombotic and non-antithrombotic patients did not differ in their hemoglobin decline or need for red blood cell transfusions while taking tigecycline.
Conclusion
A longer treatment duration, cefoperazone/sulbactam combination therapy, and a lower level of fibrinogen before tigecycline were associated with an increased risk of tigecycline-induced hypofibrinogenemia. A combination of antithrombotic drugs and tigecycline did not aggravate the bleeding events during tigecycline treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zitieren
APA
Lin, C., Tan, M., Wang, D., Gu, C., Wu, Y., & Wang, S. (2023). Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study. Pharmacology. https://doi.org/10.1159/000532001
Vancouver
Lin C, Tan M, Wang D, Gu C, Wu Y, Wang S. Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study. Pharmacology. 2023. doi:10.1159/000532001
BibTeX
@article{Lin2023,
author = {Lin, Chuwen and Tan, Miaoqin and Wang, Dongmei and Gu, Chunping and Wu, Yongming and Wang, Shengnan},
title = {Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study},
journal = {Pharmacology},
year = {2023},
doi = {10.1159/000532001}
}
EUVIMED